DaVita healthCare Partners Inc Stock News

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

MDV, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 16, 2023.

DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

DaVita Inc. (DVA) Q3 2023 Earnings Call Transcript

Dialysis firm DaVita raises its full-year 2023 adjusted profit per share outlook after beating quarterly revenue estimates, on the back of strong demand, sending shares up nearly 6% in extended tradin

Warren Buffett, the CEO of Berkshire Hathaway, is world famous and a closely watched market force. Berkshire is a big shareholder of Apple, one of the seven big tech companies that currently dominate

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with DaVita HealthCare (DVA) and Chemed (CHE). But which of these two stocks offers value investors a better

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.

DaVita (NYSE: DVA) stock price has come under intense pressure in the past few days. The stock made a big dive on October 9th and crashed to a multi-month low of $71.45.

We know Warren Buffett likes to make big bets on business. Apple (NASDAQ: AAPL ) is famously one of the largest Warren Buffett stocks, accounting for nearly one-half of Berkshire Hathaway's (NYSE: BRK

DENVER , Oct. 17, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, November 7, 2023, at 5:0

Dialysis company DaVita Inc. DVA, -16.86% issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatment for type 2 diabetes delayed the progression of c

Dialysis firm DaVita said on Thursday it believes that early success of Novo Nordisk's diabetes drug Ozempic in kidney disease trial will have "limited application" to overall patients suffering from